1047 related articles for article (PubMed ID: 33175991)
1. Update 2020: Management of Non-Small Cell Lung Cancer.
Alexander M; Kim SY; Cheng H
Lung; 2020 Dec; 198(6):897-907. PubMed ID: 33175991
[TBL] [Abstract][Full Text] [Related]
2. Non-Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment.
Duma N; Santana-Davila R; Molina JR
Mayo Clin Proc; 2019 Aug; 94(8):1623-1640. PubMed ID: 31378236
[TBL] [Abstract][Full Text] [Related]
3. Targeted therapy of oncogenic-driven advanced non-small cell lung cancer: recent advances and new perspectives.
Genova C; Rossi G; Tagliamento M; Rijavec E; Biello F; Cerbone L; Zullo L; Grossi F
Expert Rev Respir Med; 2020 Apr; 14(4):367-383. PubMed ID: 31917616
[No Abstract] [Full Text] [Related]
4. Developments in targeted therapy & immunotherapy-how non-small cell lung cancer management will change in the next decade: a narrative review.
Li MSC; Mok KKS; Mok TSK
Ann Transl Med; 2023 Aug; 11(10):358. PubMed ID: 37675321
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of immunotherapy in patients with oncogene-driven non-small-cell lung cancer: a systematic review and meta-analysis.
Chen J; Lu W; Chen M; Cai Z; Zhan P; Liu X; Zhu S; Ye M; Lv T; Lv J; Song Y; Wang D
Ther Adv Med Oncol; 2024; 16():17588359231225036. PubMed ID: 38420602
[TBL] [Abstract][Full Text] [Related]
6. [Chinese Medical Association guideline for clinical diagnosis and treatment of lung cancer (2023 edition)].
;
Zhonghua Zhong Liu Za Zhi; 2023 Jul; 45(7):539-574. PubMed ID: 37460438
[TBL] [Abstract][Full Text] [Related]
7. Molecularly targeted therapies in non-small-cell lung cancer annual update 2014.
Morgensztern D; Campo MJ; Dahlberg SE; Doebele RC; Garon E; Gerber DE; Goldberg SB; Hammerman PS; Heist RS; Hensing T; Horn L; Ramalingam SS; Rudin CM; Salgia R; Sequist LV; Shaw AT; Simon GR; Somaiah N; Spigel DR; Wrangle J; Johnson D; Herbst RS; Bunn P; Govindan R
J Thorac Oncol; 2015 Jan; 10(1 Suppl 1):S1-63. PubMed ID: 25535693
[TBL] [Abstract][Full Text] [Related]
8. Treatment of Non-Small-Cell Lung Cancer Based on Circulating Cell-Free DNA and Impact of Variation Allele Frequency.
Bustamante Alvarez JG; Janse S; Owen DH; Kiourtsis S; Bertino EM; He K; Carbone DP; Otterson GA
Clin Lung Cancer; 2021 Jul; 22(4):e519-e527. PubMed ID: 33414052
[TBL] [Abstract][Full Text] [Related]
9. Biological therapies in nonsmall cell lung cancer.
Zugazagoitia J; Molina-Pinelo S; Lopez-Rios F; Paz-Ares L
Eur Respir J; 2017 Mar; 49(3):. PubMed ID: 28254765
[TBL] [Abstract][Full Text] [Related]
10. Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer.
Negrao MV; Skoulidis F; Montesion M; Schulze K; Bara I; Shen V; Xu H; Hu S; Sui D; Elamin YY; Le X; Goldberg ME; Murugesan K; Wu CJ; Zhang J; Barreto DS; Robichaux JP; Reuben A; Cascone T; Gay CM; Mitchell KG; Hong L; Rinsurongkawong W; Roth JA; Swisher SG; Lee J; Tsao A; Papadimitrakopoulou V; Gibbons DL; Glisson BS; Singal G; Miller VA; Alexander B; Frampton G; Albacker LA; Shames D; Zhang J; Heymach JV
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34376553
[TBL] [Abstract][Full Text] [Related]
11. [Molecular pathology of lung cancer in routine diagnostic practice: 2017 update].
Matěj R; Rohan Z; Němejcová K; Dundr P
Cesk Patol; 2017; 53(4):159-166. PubMed ID: 29227119
[TBL] [Abstract][Full Text] [Related]
12. Management of non-small cell lung cancer in the era of personalized medicine.
Rocco G; Morabito A; Leone A; Muto P; Fiore F; Budillon A
Int J Biochem Cell Biol; 2016 Sep; 78():173-179. PubMed ID: 27425397
[TBL] [Abstract][Full Text] [Related]
13. Advances in Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer: Targeted Therapy.
Giustini NP; Jeong AR; Buturla J; Bazhenova L
Clin Chest Med; 2020 Jun; 41(2):223-235. PubMed ID: 32402358
[TBL] [Abstract][Full Text] [Related]
14. New update to the guidelines on testing predictive biomarkers in non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology.
Isla D; Lozano MD; Paz-Ares L; Salas C; de Castro J; Conde E; Felip E; Gómez-Román J; Garrido P; Enguita AB
Clin Transl Oncol; 2023 May; 25(5):1252-1267. PubMed ID: 36571695
[TBL] [Abstract][Full Text] [Related]
15. Current WHO guidelines and the critical role of immunohistochemical markers in the subclassification of non-small cell lung carcinoma (NSCLC): Moving from targeted therapy to immunotherapy.
Osmani L; Askin F; Gabrielson E; Li QK
Semin Cancer Biol; 2018 Oct; 52(Pt 1):103-109. PubMed ID: 29183778
[TBL] [Abstract][Full Text] [Related]
16. [Chinese Medical Association guideline for clinical diagnosis and treatment of lung cancer (2023 edition)].
;
Zhonghua Yi Xue Za Zhi; 2023 Jul; 103(27):2037-2074. PubMed ID: 37455124
[TBL] [Abstract][Full Text] [Related]
17. Optimal Management of Patients with Advanced NSCLC Harboring High PD-L1 Expression and Driver Mutations.
Chen JA; Riess JW
Curr Treat Options Oncol; 2020 Jun; 21(7):60. PubMed ID: 32588244
[TBL] [Abstract][Full Text] [Related]
18. Targeted therapy in lung cancer: Are we closing the gap in years of life lost?
Benjamin DJ; Haslam A; Gill J; Prasad V
Cancer Med; 2022 Sep; 11(18):3417-3424. PubMed ID: 35315222
[TBL] [Abstract][Full Text] [Related]
19. Comprehensive molecular analysis of driver mutations in non-small cell lung carcinomas and its correlation with PD-L1 expression, An Indian perspective.
Aggarwal A; Sharma S; Brar Z; Kumar V; Kumar A; Katara R; Mohanty SK
Pathol Res Pract; 2024 Jan; 253():155013. PubMed ID: 38096714
[TBL] [Abstract][Full Text] [Related]
20. Resistance to molecularly targeted therapy in non-small-cell lung cancer.
Asao T; Takahashi F; Takahashi K
Respir Investig; 2019 Jan; 57(1):20-26. PubMed ID: 30293943
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]